<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01628068</url>
  </required_header>
  <id_info>
    <org_study_id>ELIGIBLE</org_study_id>
    <secondary_id>Estudio ELIGIBLE</secondary_id>
    <nct_id>NCT01628068</nct_id>
  </id_info>
  <brief_title>ELIGIBLE (Efficacy of Left atrIal Appendage Closure After GastroIntestinal BLEeding)</brief_title>
  <acronym>ELIGIBLE</acronym>
  <official_title>Efficacy of Left Atrial Appendage Closure After Gastrointestinal Bleeding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with atrial fibrillation requiring anticoagulation treatment are at high risk of&#xD;
      gastrointestinal bleeding. The investigators propose the percutaneous stop the oral&#xD;
      anticoagulation and closure of the left atrial appendage with the Amplatzer ® system in&#xD;
      patients receiving anticoagulant therapy for atrial fibrillation without associated valvular&#xD;
      heart disease, to reduce significantly the risk of stroke while minimizing the risk of&#xD;
      bleeding in a group of patients with high risk for both events.&#xD;
&#xD;
      ELIGIBLE trial(Left atrial appendage Efficacy of GastroIntestinal Bleeding after closure) is&#xD;
      a prospective, multicentric and randomized (2 to 1) trial, comparing percutaneous closure of&#xD;
      atrial appendage left versus standard treatment with oral anticoagulants in patients with&#xD;
      history of gastrointestinal bleeding and high embolic risk.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined overall mortality, major bleeding, stroke or procedure-related complications</measure>
    <time_frame>1 year</time_frame>
    <description>The primary end point will be at one year the combined overall mortality, major bleeding, stroke or procedure-related complications.&#xD;
Mortality from any cause&#xD;
Severe bleeding defined according to VARC criteria&#xD;
Ischemic stroke or hemorrhagic stroke at 12 months.&#xD;
Complications related to the procedure: include:&#xD;
device embolization&#xD;
severe pericardial effusion with hemodynamic compromise that requires drainage&#xD;
Device thrombosis&#xD;
cardiac perforation&#xD;
major local complications (according to definitions of VARC)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Adverse Reaction to Drugs Affecting the Gastrointestinal System</condition>
  <arm_group>
    <arm_group_label>Left atrial appendage occlusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Left atrial appendage occlusion with Amplatzer device plus aspirine plus clopidogrel during 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral anticoagulation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Oral anticoagulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Left atrial appendage occlusion</intervention_name>
    <description>Left atrial appendage occlusion with Amplatzer device plus aspirine plus clopidogrel during 3 months</description>
    <arm_group_label>Left atrial appendage occlusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  documented atrial fibrilation (paroxysmal or permanent) without significant heart&#xD;
             valve disease&#xD;
&#xD;
          -  &gt; 18 years&#xD;
&#xD;
          -  Classic oral anticoagulation(INR at therapeutic levels: 2-3) or New oral&#xD;
             anticoagulants&#xD;
&#xD;
          -  CHA2-DS2-VASC score ≥ 3&#xD;
&#xD;
          -  prior digestive bleeding without any treatable cause&#xD;
&#xD;
          -  Informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  POF&#xD;
&#xD;
          -  contraindication to further treatment with dual antiplatelet therapy (aspirin +&#xD;
             clopidogrel)&#xD;
&#xD;
          -  Intracardiac thrombus&#xD;
&#xD;
          -  significant carotid disease&#xD;
&#xD;
          -  Cardioversion scheduled within 30 days following the implantation&#xD;
&#xD;
          -  AF not controlled by FVM&gt; 100 bpm&#xD;
&#xD;
          -  AF secondary to surgery or ablation&#xD;
&#xD;
          -  thrombosis in patients &lt;40 years&#xD;
&#xD;
          -  chronic renal insufficiency with Cr clearance &lt;30 ml 2&#xD;
&#xD;
          -  left appendage sizeappendage with inlet &lt;12.6 mm or &gt; 28.5 (ETE)&#xD;
&#xD;
          -  depth of the appendage &lt;10mm in the TEE&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Victoria Martín Yuste, MD, PhD</last_name>
    <phone>+34-93-227-55-19</phone>
    <email>vmartiny@clinic.ub.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <state>Mdrid</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Goicolea, MD</last_name>
    </contact>
    <investigator>
      <last_name>Javier Goicolea, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>José Antonio Fernández Díaz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Cristina</name>
      <address>
        <city>Badajoz</city>
        <zip>06006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Ramón López Mínguez, MD, PhD</last_name>
      <phone>+34-924218100</phone>
      <email>lópez-mínguez@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>José Ramón López Mínguez, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundació Clínic per a la Recerca Biomèdica</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Martín Yuste, MD, PhD</last_name>
      <phone>+34-932275400</phone>
      <email>vmartiny@clinic.ub.es</email>
    </contact>
    <investigator>
      <last_name>Victoria Martín Yuste, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manel Sabaté Tenas, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raúl Moreno, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Raúl Moreno, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José María Hernández García, MD</last_name>
    </contact>
    <investigator>
      <last_name>José María Hernández García, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Macarena</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Ruiz Salmerón, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rafael Ruiz Salmerón, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>June 22, 2012</study_first_submitted>
  <study_first_submitted_qc>June 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2012</study_first_posted>
  <last_update_submitted>June 25, 2012</last_update_submitted>
  <last_update_submitted_qc>June 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Victoria Martin Yuste</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Left atrial appendage occlusion</keyword>
  <keyword>gastrointestinal bleeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

